PMID- 33779081
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 62
IP  - 4
DP  - 2021 Apr
TI  - Serological Biomarkers and Indices for the Current Activity and Prognosis of 
      ANCA-Associated Vasculitis: Experience in a Single Centre in Korea.
PG  - 279-287
LID - 10.3349/ymj.2021.62.4.279 [doi]
AB  - Small vessel vasculitis is composed of two types of vasculitis based on 
      immune-complex deposits, immune-complex vasculitis and antineutrophil cytoplasmic 
      antibody-associated vasculitis (AAV) according to the 2012 Chapel Hill Consensus 
      Conferences Nomenclature of Vasculitis. In general, the current disease-states 
      are assessed in three ways in real clinical practice such as activity, damage and 
      functional status. Birmingham vasculitis activity score (BVAS, version 3) and 
      five-factor score were calculated for assessing the cross-sectional activity and 
      for predicting the prognosis of AAV, respectively. Since BVAS includes a wide 
      spectrum of nine systemic items with differently weighted scores based on 
      new-onset/worsening or persistent each symptom, it has been considered as the 
      most reliable tool to assess AAV activity to date. However, since BVAS represents 
      both cross-sectional and chronic clinical features, it has a limitation in 
      flexibly reflecting the cross-sectional activity or severity of AAV. In addition, 
      the heterogeneous items of BVAS are difficult to reflect the close correlation 
      between BVAS and AAV pathogenesis. It is practically difficult to discover new 
      biomarkers or indices that exceed the reliability of AAV-specific indices or 
      acute-phase reactants established by long clinical experience. However, efforts 
      to discover and develop new biomarkers or indices are expected to complement the 
      clinical unmet need of existing AAV-specific indices and acute-phase reactants. 
      In this review, we reviewed the serological biomarkers and indices that have been 
      reported to date and introduced studies that investigated serological biomarkers 
      and indices in Korean patients with AAV.
CI  - (c) Copyright: Yonsei University College of Medicine 2021.
FAU - Ahn, Sung Soo
AU  - Ahn SS
AUID- ORCID: 0000-0002-9002-9880
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
FAU - Park, Yong Beom
AU  - Park YB
AUID- ORCID: 0000-0003-4695-8620
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Korea.
FAU - Lee, Sang Won
AU  - Lee SW
AUID- ORCID: 0000-0002-8038-3341
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Korea. sangwonlee@yuhs.ac.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Biomarkers)
SB  - IM
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis
MH  - *Antibodies, Antineutrophil Cytoplasmic
MH  - Biomarkers
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Prognosis
MH  - Reproducibility of Results
MH  - Republic of Korea
PMC - PMC8007433
OTO - NOTNLM
OT  - Antineutrophil cytoplasmic antibody
OT  - activity
OT  - biomarkers
OT  - indices
OT  - prognosis
OT  - serological
OT  - vasculitis
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2021/03/30 06:00
MHDA- 2021/04/28 06:00
PMCR- 2021/04/01
CRDT- 2021/03/29 07:02
PHST- 2020/11/09 00:00 [received]
PHST- 2021/01/27 00:00 [revised]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/03/29 07:02 [entrez]
PHST- 2021/03/30 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2021/04/01 00:00 [pmc-release]
AID - 62.279 [pii]
AID - 10.3349/ymj.2021.62.4.279 [doi]
PST - ppublish
SO  - Yonsei Med J. 2021 Apr;62(4):279-287. doi: 10.3349/ymj.2021.62.4.279.